Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia

Summary

This is a randomised double-blinded placebo-controlled multi centre study in 98 patients with ACPA positive arthralgia. The study is composed of 2 arms with a 1:1 randomisation at baseline: Treatment phase will be 6 months. Group 1: Abatacept s.c. 125 mg weekly for 6 months vs. Group 2: Placebo s.c. for 6 months. After 6 months both groups will run into the follow up period for another 12 months up to month 18. Patients developing arthritis will be treated according to local guidelines.

Timeline

Start

2014-11

Primary completion

2019-12

Completion

2019-12

Drugs

Indications